In-Hospital Pulmonary Arterial Embolism after Catheter Ablation of Over 45,000 Cardiac Arrhythmias: Individualized Case Analysis of Multicentric Data
CONCLUSION: Over a 15-year period, incidence of PE after ablation is low, particularly low in patients with ablation for AF/AFlu. This is most likely due to stricter anticoagulation management in these patients compared with those receiving SVT/VT ablation procedures and could argue for continuation of OAC prior to ablation. Optimizing periprocedural anticoagulation management should be subject of further prospective trials.PMID:38555641 | DOI:10.1055/s-0044-1785519 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 31, 2024 Category: Hematology Authors: Florian Doldi Nele Ge ßler Omar Anwar Ann-Kathrin Kahle Katharina Scherschel Benjamin Rath Julia K öbe Philipp Sebastian Lange Gerrit Frommeyer Andreas Metzner Christian Meyer Stephan Willems Karl-Heinz Kuck Lars Eckardt Source Type: research
In-Hospital Pulmonary Arterial Embolism after Catheter Ablation of Over 45,000 Cardiac Arrhythmias: Individualized Case Analysis of Multicentric Data
CONCLUSION: Over a 15-year period, incidence of PE after ablation is low, particularly low in patients with ablation for AF/AFlu. This is most likely due to stricter anticoagulation management in these patients compared with those receiving SVT/VT ablation procedures and could argue for continuation of OAC prior to ablation. Optimizing periprocedural anticoagulation management should be subject of further prospective trials.PMID:38555641 | DOI:10.1055/s-0044-1785519 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 31, 2024 Category: Hematology Authors: Florian Doldi Nele Ge ßler Omar Anwar Ann-Kathrin Kahle Katharina Scherschel Benjamin Rath Julia K öbe Philipp Sebastian Lange Gerrit Frommeyer Andreas Metzner Christian Meyer Stephan Willems Karl-Heinz Kuck Lars Eckardt Source Type: research
Hormonal contraceptive use after a first venous thrombotic event and the risk of recurrence in premenopausal women
CONCLUSIONS: CHC use after a first VTE is safe during anticoagulant use, but substantially increases the risk of a recurrent VTE event in absence of anticoagulant use. This study adds to the evidence regarding a levonorgestrel-releasing intra-uterine device as a safe alternative.PMID:38554933 | DOI:10.1016/j.jtha.2024.03.014 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 30, 2024 Category: Hematology Authors: Judith P L Verlaan Bernadine H Stegeman Jasmijn F Timp Luuk J J Scheres Linda E Flinterman Frans M Helmerhorst Frits R Rosendaal Suzanne C Cannegieter Astrid van Hylckama Vlieg Source Type: research
Disparities in access and timing of interventional therapies for pulmonary embolism across the United States
CONCLUSIONS: Significant racial, sex-based and geographic barriers exist in overall access to IT for PE in the United States.PMID:38554934 | DOI:10.1016/j.jtha.2024.03.013 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 30, 2024 Category: Hematology Authors: Barret Rush Jennifer Ziegler Stephanie Dyck Surinder Dhaliwal Owen Mooney Sylvain Lother Leo Anthony Celi Asher Mendelson Source Type: research
Diagnosis of thrombotic thrombocytopenic purpura: Easy-to-use fiber-optic surface plasmon resonance immunoassays for automated ADAMTS13 antigen and conformation evaluation
CONCLUSIONS: Both ADAMTS13 antigen and conformation assays were transferred onto automated, easy-to-use FO-SPR technology displaying potent analytical sensitivity and reproducibility. ADAMTS13 antigen and conformation were determined for healthy donors and acute iTTP patients showing strong correlation with ELISA reference. Introducing FO-SPR technology in clinical context could support routine diagnosis of acute iTTP patients, notably when ADAMTS13 activity fluctuates between 10-20%.PMID:38554935 | DOI:10.1016/j.jtha.2024.03.012 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 30, 2024 Category: Hematology Authors: Quintijn Bonnez Charlotte Dekimpe Tim Bekaert Edwige Tellier Gilles Kaplanski B érangère S Joly Agn ès Veyradier Paul Coppo Jeroen Lammertyn Claudia Tersteeg Simon F De Meyer Karen Vanhoorelbeke Source Type: research
MITD1 deficiency leads to poor survival via tissue factor-mediated coagulation in bladder cancer
CONCLUSIONS: Our findings suggest the novel role of tumor prognostic genes upon the development of hypercoagulative phenotype and venous thromboembolism, thereby underlining the importance of anticoagulant therapy and shedding light on the therapeutic value of targeting MITD1 in bladder cancer.PMID:38554936 | DOI:10.1016/j.jtha.2024.03.015 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 30, 2024 Category: Hematology Authors: Yuanbin Chen Wei Jiao Yonghua Wang Zhijuan Liang Liping Wang Dan Li Ye Liang Haitao Niu Source Type: research
Thrombocytopenia with and without thrombosis following COVID-19 vaccination: long-term management
CONCLUSION: Two of 4 patients with VITT developed refractory thrombocytopenia successfully treated with intravenous immunoglobulin, corticosteroids, and plasma exchange therapy. Patients with VITT remained on anticoagulation for at least 9 months due to persistently positive diagnostic tests. Four of 5 patients with immune thrombocytopenia received intravenous immunoglobulin and corticosteroids with good recovery. Patients who received a subsequent COVID-19 mRNA vaccine had no adverse hematologic effects.PMID:38550529 | PMC:PMC10973182 | DOI:10.1016/j.rpth.2024.102357 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 29, 2024 Category: Hematology Authors: M Ge D Ladha J Lymer S Pancic M Carrier G Le Gal L A Castellucci Source Type: research
Inositol 1,3,4,5-tetrakisphosphate: a remarkable second messenger in platelet signaling
Res Pract Thromb Haemost. 2024 Mar 1;8(2):102365. doi: 10.1016/j.rpth.2024.102365. eCollection 2024 Feb.NO ABSTRACTPMID:38550530 | PMC:PMC10973178 | DOI:10.1016/j.rpth.2024.102365 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 29, 2024 Category: Hematology Authors: Elmina Mammadova-Bach Attila Braun Source Type: research
Thrombocytopenia with and without thrombosis following COVID-19 vaccination: long-term management
CONCLUSION: Two of 4 patients with VITT developed refractory thrombocytopenia successfully treated with intravenous immunoglobulin, corticosteroids, and plasma exchange therapy. Patients with VITT remained on anticoagulation for at least 9 months due to persistently positive diagnostic tests. Four of 5 patients with immune thrombocytopenia received intravenous immunoglobulin and corticosteroids with good recovery. Patients who received a subsequent COVID-19 mRNA vaccine had no adverse hematologic effects.PMID:38550529 | PMC:PMC10973182 | DOI:10.1016/j.rpth.2024.102357 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 29, 2024 Category: Hematology Authors: M Ge D Ladha J Lymer S Pancic M Carrier G Le Gal L A Castellucci Source Type: research
Inositol 1,3,4,5-tetrakisphosphate: a remarkable second messenger in platelet signaling
Res Pract Thromb Haemost. 2024 Mar 1;8(2):102365. doi: 10.1016/j.rpth.2024.102365. eCollection 2024 Feb.NO ABSTRACTPMID:38550530 | PMC:PMC10973178 | DOI:10.1016/j.rpth.2024.102365 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 29, 2024 Category: Hematology Authors: Elmina Mammadova-Bach Attila Braun Source Type: research
Thrombocytopenia with and without thrombosis following COVID-19 vaccination: long-term management
CONCLUSION: Two of 4 patients with VITT developed refractory thrombocytopenia successfully treated with intravenous immunoglobulin, corticosteroids, and plasma exchange therapy. Patients with VITT remained on anticoagulation for at least 9 months due to persistently positive diagnostic tests. Four of 5 patients with immune thrombocytopenia received intravenous immunoglobulin and corticosteroids with good recovery. Patients who received a subsequent COVID-19 mRNA vaccine had no adverse hematologic effects.PMID:38550529 | PMC:PMC10973182 | DOI:10.1016/j.rpth.2024.102357 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 29, 2024 Category: Hematology Authors: M Ge D Ladha J Lymer S Pancic M Carrier G Le Gal L A Castellucci Source Type: research
Inositol 1,3,4,5-tetrakisphosphate: a remarkable second messenger in platelet signaling
Res Pract Thromb Haemost. 2024 Mar 1;8(2):102365. doi: 10.1016/j.rpth.2024.102365. eCollection 2024 Feb.NO ABSTRACTPMID:38550530 | PMC:PMC10973178 | DOI:10.1016/j.rpth.2024.102365 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 29, 2024 Category: Hematology Authors: Elmina Mammadova-Bach Attila Braun Source Type: research
Changes in fibrin clot properties in patients after Roux-en-Y gastric bypass surgery
CONCLUSION: RYGB surgery led to a decrease in the maximum absorbance of the fibrin clot. Values of maximum absorbance were associated with measures of glycemic control and inflammation. In contrast to previous reports, fibrin clot lysis time was not affected after surgery.PMID:38545128 | PMC:PMC10966290 | DOI:10.1016/j.rpth.2024.102361 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 28, 2024 Category: Hematology Authors: Kazim Abbas Stephen J Hierons Nikoletta Pechlivani Fladia Phoenix Robin Alexander Rhodri King Ramzi A Ajjan Alan J Stewart Source Type: research
Extending Venous Thromboembolism Secondary Prevention with Apixaban in Cancer Patients. The EVE Trial
CONCLUSION: For secondary prevention of cancer associated VTE, Apixaban 2.5 mg compared to 5 mg twice daily did not lower combined bleeding events. (EVE trial. NCT03080883).PMID:38537780 | DOI:10.1016/j.jtha.2024.03.011 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 27, 2024 Category: Hematology Authors: Robert D McBane Charles L Loprinzi Tyler Zemla Alfonso Tafur Kristen Sanfilippo Jane Jijun Liu David A Garcia James Heun Krishna Gundabolu Adedayo A Onitilo Usha Perepu Monic R Drescher Stanislav Henkin Damon Houghton Aneel Ashrani Henny Billett Shaylene Source Type: research
SETD2 Promotes Megakaryocyte Polyploidization and Platelet Generation through Methylation of α-tubulin
CONCLUSION: These findings identify a previously unrecognized role for SETD2 in regulating megakaryopoiesis and highlight the potential of targeting SETD2 to increase platelet production from human cells for transfusion practices.PMID:38537781 | DOI:10.1016/j.jtha.2024.03.010 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 27, 2024 Category: Hematology Authors: Lei Chen Jingkun Liu Kunying Chen Yanxun Su Yihe Chen Ying Lei Jia Si Jie Zhang Zhaojun Zhang Weiguo Zou Xiaohui Zhang Matthew T Rondina Qian-Fei Wang Yueying Li Source Type: research
